SCHEMBL993745

SCHEMBL993745

CCCCc1ccccc1N=C=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
GABRA1 P14867 2/20 0.47
GABRB2 P47870 2/20 0.47
LIPG Q9Y5X9 1/20 0.40
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
TLR8 Q9NR97 1/20 0.35
BID P55957 3/20 0.34
MCL1 Q07820 3/20 0.34
BCL2L1 Q07817 2/20 0.34
BAK1 Q16611 2/20 0.34
KAT8 Q9H7Z6 2/20 0.34
CTRC Q99895 1/20 0.34
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34
EP300 Q09472 1/20 0.34
KAT2A Q92830 1/20 0.34
KAT2B Q92831 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29651833 1.00 CYP3A4 (0.51) CYP3A4CYP2D6CYP2C9GABRA1GABRB2
SCHEMBL2350176 0.95 CYP3A4 (0.46) CYP3A4CYP2D6CYP2C9GABRA1GABRB2
SCHEMBL5885134 0.93 LIPG (0.49) CYP3A4CYP2D6CYP2C9GABRA1GABRB2
SCHEMBL5885474 0.93 LIPG (0.49) CYP3A4CYP2D6CYP2C9GABRA1GABRB2
SCHEMBL10400982 0.93 LIPG (0.49) CYP3A4CYP2D6CYP2C9GABRA1GABRB2
SCHEMBL13725696 0.93 LIPG (0.49) CYP3A4CYP2D6CYP2C9GABRA1GABRB2
SCHEMBL5885574 0.93 LIPG (0.49) CYP3A4CYP2D6CYP2C9GABRA1GABRB2
SCHEMBL5884676 0.93 LIPG (0.49) CYP3A4CYP2D6CYP2C9GABRA1GABRB2
SCHEMBL5885360 0.93 LIPG (0.49) CYP3A4CYP2D6CYP2C9GABRA1GABRB2
SCHEMBL29554576 0.93 LIPG (0.49) CYP3A4CYP2D6CYP2C9GABRA1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3873962-A2 METHOD FOR THE PRODUCTION OF THERMOPLASTIC POLYOXAZOLIDINONE POLYMERS Covestro Intellectual Property GmbH & Co. KG (DE) 2021-09-08 EP claimed
EP-3681924-A1 METHOD FOR THE PRODUCTION OF THERMOPLASTIC POLYOXAZOLIDINONE POLYMERS Covestro Deutschland AG (DE) 2020-07-22 EP claimed
EP-3500611-A1 PROCESS FOR THE SYNTHESIS OF POLYOXAZOLIDINONE COMPOUNDS Covestro Deutschland AG (DE) 2019-06-26 EP claimed
WO-2019052994-A1 METHOD FOR THE PRODUCTION OF THERMOPLASTIC POLYOXAZOLIDINONE POLYMERS COVESTRO DEUTSCHLAND AG (DE) 2019-03-21 WO claimed
WO-2018033562-A1 PROCESS FOR THE SYNTHESIS OF POLYOXAZOLIDINONE COMPOUNDS COVESTRO DEUTSCHLAND AG (DE) 2018-02-22 WO claimed
EP-3256508-A1 PROCESS FOR THE SYNTHESIS OF POLYOXAZOLIDINONE COMPOUNDS WITH HIGH STABILITY Covestro Deutschland AG (DE) 2017-12-20 EP claimed
WO-2016128380-A1 PROCESS FOR THE SYNTHESIS OF POLYOXAZOLIDINONE COMPOUNDS WITH HIGH STABILITY COVESTRO DEUTSCHLAND AG (DE) 2016-08-18 WO claimed
US-20240001334-A1 ACTIVE HYDROGEN-CONTAINING ORGANIC COMPOUND SCAVENGER, COMPOSITION, AND APPLICATIONS THEREOF TOSOH CORPORATION (JP) 2024-01-04 US disclosed
WO-2021211123-A1 ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA UNIVERSITY OF NOTRE DAME DU LAC (US) 2021-10-21 WO disclosed
EP-2078724-B1 PROCESS FOR PRODUCTION OF DIALKYLTIN DIALKOXIDES ASAHI CHEMICAL IND (JP) 2016-11-30 EP disclosed
CN-104870517-A FLUORENE-BASED POLYMER, FLUORENE-BASED DIOL COMPOUND AND METHOD FOR PRODUCING SAME TAOKA CHEMICAL CO LTD 2015-08-26 CN disclosed
CN-104812797-A Fluorene polymer, fluorene diol compound, and method for producing said polymer and compound TAOKA CHEMICAL CO LTD 2015-07-29 CN disclosed
US-8008518-B2 Process for producing dialkyl tin dialkoxides ASAHI KASEI CHEMICALS CORPORATION (JP) 2011-08-30 US disclosed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN disclosed
EP-1465858-A2 PHENY(ALKYL)CARBOXYLIC ACID DERIVATIVES AND DIONIC PHENYLALKYLHETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDICINES WITH SERUM GLUCOSE AND/OR SERUM LIPID LOWERING ACTIVITY Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 2004-10-13 EP disclosed
WO-2004009549-A2 PIPERIDINES USEFUL FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ACTELION PHARMACEUTICALS LTD (CH) 2004-01-29 WO disclosed
WO-2003059864-A2 PHENY(ALKYL)CARBOXYLIC ACID DERIVATIVES AND DIONIC PHENYLALKYLHETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDICINES WITH SERUM GLUCOSE AND/OR SERUM LIPID LOWERING ACTIVITY SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2003-07-24 WO disclosed
US-4041019-A 1-(N-SUBSTITUTED CARBAMOYL)-IMIDAZOLES THE DOW CHEMICAL COMPANY (US) 1977-08-09 US disclosed
US-3961061-A INSECTICIDES, FUNGICIDES, BACTERICIDES, MITICIDES BAYER AKTIENGESELLSCHAFT (DT) 1976-06-01 US disclosed
US-3933701-A High resilience polyurethane foam OLIN CORPORATION (US) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240001334-A1 ACTIVE HYDROGEN-CONTAINING ORGANIC COMPOUND SCAVENGER, COMPOSITION, AND APPLICATIONS THEREOF CBR1, ADH1C, ADH1A CYP3A4 774/4885CYP2D6 3565/4885CYP2C9 1211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.